Member Info for hasiba

I like to think there’s a plan ahead as there will be no point to carry on and doing all this if they see no real value in Iclaprim. I still think we may come out with some good after all. Then yesterday rns is a hint of business as usual to explore other applications for Iclaprim.
Hope is there or a pie in the sky!!
Me thinking hope and value trap. Will see
Dyor. Big gamble and highly r
isky

There is a hope of value in this rns...
The shareholders will have to vote for it to get some money back..who knows how much would be sold for...game is on as I see it but jam later.

And the trading volumes on nasdaq and here over 20x the average!
Well I hope ,and how it looks now is game still on!
We need Mystic Meg’s Wheel of Destiny!

Kettle...I understand the rns as Iclaprim effectiveness is the main issue..
“ David Huang, M.D., Ph.D., Chief Medical Officer of Motif Bio, said: "When a wound becomes infected, it is critical to provide safe and effective treatment as fast as possible. The data generated from Dr. Zurawski's research will be important in understanding whether iclaprim delivered locally could play a role in treating battlefield wound infections.”

Blue it is!
Today sp holds well in a tight range.
Bodes well for tomorrow...fingers crossed...

Rollercoaster rides at Nasdaq too.....hold to your seat so no body can be thrown out into the ditch!!
Wtf is going on here..

Up 30% hope it holds,

And would any goverment give a grant to a drug company involved in a litigation, with one of its most important departments , that may be convected of serious wrong doings to its nation!!
It doesn’t make any sense unless they know the case against Indv is weak and likely to be dismissed.
The worse scenario imv would be a slap on the wrist with a small fine..
Indv current sp is ridiculously cheap...and the whole doj litigation is well overblown .
Holding strong and positive.

Blue finish anyone?!

First ...We need more details on today’s news...
But it does show Iclaprim potentials in many fields...where many are still interested.
The whole issue with motif is the inexperienced bod..headed by mistrusted ceo..
Changes must take place to gain trust and confidence in motif..and scared to invest .
Market and investors lost confidence in this management with their over inflated salaries characteristic of greedily lots. Simply bunch of muppets imo.
I do not know what we are going to hear in the incoming general meeting and if I can trust what is going to be said..
We need credible and experienced bod and a new ceo and I hope a buyer will come along to save motif and Iclaprim very soon.

I think we may have seen the low of the low in sp yesterday..
Time hopefully to consolidate and move upwards..
I would add at this sp but accumulated enough numbers for my risk appetite!

Scotty is busy ,meeting Genius for afternoon tea at the Dorchester Park Lane!!
Imagine the subject of discussion between them?!

Excellent news with a new life injected into motif.
Reassuring and no bust in the short term at least.
Share price must reflect in a big way here.

In one week sp is down by 24%!! with no news.
Let’s hope a nice blue recovery tomorrow....any fortune teller here?
Or rns from indv ..

Summary..
https://twitter.com/Metro_Bank/status/1187035042146594823?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1187035042146594823&ref_url=https%3A%2F%2Fwww.eveningexpress.co.uk%2Fnews%2Fbusiness%2Fmetro-bank-reveals-profit-plunge-after-challenging-period%2F

It doesn’t make sense to short indv as you are taking huge risks and potential multiples of losses.
That is why no sig. shorts reported .

Eviking..you are very brave...
I need to tune my pacemaker to reach your steel fortitude!..

The costs of USA government by opioid addiction is near the $650 billion a year and surely 23 b over 10 years free offers by Teva for inferior product is not going to be something they consider seriously if there is a better product to use which is a better value and treatment in the long run and politically is not going to work if patients prefer to take the better product ,but the government would not allow it because there is an inferior product is available for free!!
I think the issue is mainly if there is a settlement with the doj and by how much Or a dismissal which I don’t think so.....it will have to be a settlement in a feww hundreds millions or hopefully less.

I think if we should read indv latest revenue and profit upgrades again so we know exactly where their main increasing income and increasing profits are coming from ...to clarify

But the new preferred product of indv is the one that is a preferred product which Teva is not offering....and this is bringing the most revenue and increasing profits..otherwise we wouldn’t see this even at present if not so.
Or you have a different facts that we are not aware of?